S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
NASDAQ:MNMD

Mind Medicine (MindMed) (MNMD) Stock Price, News & Analysis

$4.77
+0.15 (+3.25%)
(As of 02/22/2024 ET)
Today's Range
$4.54
$4.90
50-Day Range
$3.35
$5.07
52-Week Range
$2.41
$5.35
Volume
629,391 shs
Average Volume
646,197 shs
Market Capitalization
$191.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.50

Mind Medicine (MindMed) MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
392.7% Upside
$23.50 Price Target
Short Interest
Bearish
12.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Mind Medicine (MindMed) in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$93,157 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.16) to ($1.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.17 out of 5 stars

Medical Sector

772nd out of 934 stocks

Medicinals & Botanicals Industry

9th out of 10 stocks


MNMD stock logo

About Mind Medicine (MindMed) Stock (NASDAQ:MNMD)

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company working to develop therapies and treatments based on psychoactive substances. The company develops novel products including psychoactive substances and digital medicine to treat brain health disorders related to psychiatry, addiction, pain, and neurology. Digital medicine is the use of technology to measure and intervene in the service of human health and is a budding industry of its own. The company has 10 compounds in pre-clinical or clinical trials and 4 are on track to advance to Phase 1. The company is headquartered in Vancouver, Canada.

Mind Medicine’s pipeline of drug candidates is based on emerging science that more than suggests psychoactive substances can be used to relieve stress and anxiety disorders in the brain. Among the many potential uses for these drugs is the treatment of anxiety and stress related to PTSD and secondary stress disorders related to the treatment of people suffering from stress and anxiety-related disorders. Psychoactive compounds have also been shown to be effective in treating autism, pain, and social disorders.

The company’s treatments are focused on neuroplasticity or the fact our brain function is tied to its structure and the structure of our brains can change over time. When used in the proper context, Mind Medicine’s treatments aid the restructuring of brain activity and how it organizes information by catalyzing plasticity. In some cases, patients under treatment learn to make positive associations in relation to stress-inducing stimuli while under the influence of the treatments.

In addition to plasticity, psychoactive drugs like LSD, psilocybin, and DMT have been shown to have experiential effects such as lowering mental barriers and reducing defensive and often reflexive mechanisms that can be an impediment to healing.

Among the benefits of using psychoactive compounds versus traditional therapeutics are the speed of efficacy and greatly reduced side effects. Psychoactive drugs can produce positive effects in patients with the first use while it may take weeks for the current treatments to take effect and they come with many side effects. In some cases, side effects of mainstream treatments include an increase in suicidal behavior.

The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain. MM-120 is LSD D-tartrate. MM-110 is a nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal.

Mind Medicine also develops MM-402 which is for the treatment of core symptoms of autism spectrum disorder. This treatment is based on MDMA and improves sociability in autistic patients without stimulants and is shown to have superior safety and tolerability.

 

MNMD Stock Price History

MNMD Stock News Headlines

Elon Musk's "Project Dojo" is a Game-Changer
Morgan Stanley predicts that Musk's latest act will boost Tesla's shares by 80% in the next 12 months. But if you want to profit from this development, you'll buy the firm that could see its sales explode by 829% as "Project Dojo" sweeps the nation.
Why Is MindMed (MNMD) Stock Up 8% Today?
Elon Musk's "Project Dojo" is a Game-Changer
Morgan Stanley predicts that Musk's latest act will boost Tesla's shares by 80% in the next 12 months. But if you want to profit from this development, you'll buy the firm that could see its sales explode by 829% as "Project Dojo" sweeps the nation.
Mind Medicine (MindMed) Inc. (MMQ.F)
MNMD Mind Medicine (MindMed) Inc.
7 Best Psychedelic Stocks to Watch
See More Headlines
Receive MNMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mind Medicine (MindMed) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/22/2024
Next Earnings (Estimated)
3/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:MNMD
Fax
N/A
Employees
48
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.50
High Stock Price Target
$75.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+392.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-56,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.97 per share

Miscellaneous

Free Float
39,249,000
Market Cap
$191.28 million
Optionable
Optionable
Beta
2.44
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Robert Barrow (Age 35)
    CEO & Director
    Comp: $956.1k
  • Mr. Schond L. Greenway M.B.A. (Age 52)
    Chief Financial Officer
    Comp: $343.28k
  • Dr. Daniel Rollings Karlin M.A. (Age 43)
    M.D., Chief Medical Officer
    Comp: $663.63k
  • Dr. Miriam Halperin Wernli Ph.D. (Age 71)
    Executive President
    Comp: $552.46k
  • Dr. Scott M. Freeman M.D. (Age 67)
    Co-Founder & Clinical Advisor
    Comp: $317.58k
  • Mr. Leonard Latchman
    Co-founder
  • Ms. Carrie F. Liao CPA
    CGMA, VP & Chief Accounting Officer
  • Mr. Maxim Jacobs C.F.A.
    Vice President of Investor Relations & Corporate Communications
  • Mr. Mark R. Sullivan J.D. (Age 53)
    Chief Legal Officer & Corporate Secretary
  • Dr. Francois P. Lilienthal M.B.A.
    M.D., Chief Commercial Officer














MNMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Mind Medicine (MindMed) stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mind Medicine (MindMed) in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MNMD shares.
View MNMD analyst ratings
or view top-rated stocks.

What is Mind Medicine (MindMed)'s stock price target for 2024?

6 brokers have issued 12 month price objectives for Mind Medicine (MindMed)'s stock. Their MNMD share price targets range from $7.00 to $75.00. On average, they expect the company's share price to reach $23.50 in the next twelve months. This suggests a possible upside of 392.7% from the stock's current price.
View analysts price targets for MNMD
or view top-rated stocks among Wall Street analysts.

How have MNMD shares performed in 2024?

Mind Medicine (MindMed)'s stock was trading at $3.66 on January 1st, 2024. Since then, MNMD shares have increased by 30.3% and is now trading at $4.77.
View the best growth stocks for 2024 here
.

When is Mind Medicine (MindMed)'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our MNMD earnings forecast
.

What ETF holds Mind Medicine (MindMed)'s stock ?

AdvisorShares Psychedelics ETF holds 123,228 shares of MNMD stock, representing 7.16% of its portfolio.

When did Mind Medicine (MindMed)'s stock split?

Shares of Mind Medicine (MindMed) reverse split on the morning of Monday, August 29th 2022. The 1-15 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Mind Medicine (MindMed)'s major shareholders?

Mind Medicine (MindMed)'s stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Charles Schwab Investment Management Inc. (0.48%), Busey Bank (0.39%), Cresset Asset Management LLC (0.39%), Scotia Capital Inc. (0.30%), AdvisorShares Investments LLC (0.28%) and Goldman Sachs Group Inc. (0.28%). Insiders that own company stock include Dan Karlin, Robert Barrow and Schond L Greenway.
View institutional ownership trends
.

How do I buy shares of Mind Medicine (MindMed)?

Shares of MNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MNMD) was last updated on 2/23/2024 by MarketBeat.com Staff